CCL2 and IL18 expressions may associate with the anti-proliferative effect of noncontact electro capacitive cancer therapy in vivo

0303 health sciences Tumor Necrosis Factor-alpha Interleukin-18 Mammary Neoplasms, Experimental Electric Stimulation Therapy Rats 3. Good health Rats, Sprague-Dawley 03 medical and health sciences Interleukin-23 Subunit p19 Animals Female Chemokine CCL2 Research Article Cell Proliferation
DOI: 10.12688/f1000research.20727.1 Publication Date: 2019-10-17T13:05:07Z
ABSTRACT
<ns4:p><ns4:bold>Background:</ns4:bold> Noncontact Electro Capacitive Cancer Therapy (ECCT) is a novel treatment modality in cancer. Chemokine (C-C motif) ligand 2 (CCL2) has major role the outgrowth of metastatic breast Interleukin 18 (IL18) plays macrophage alteration, which leads to excessive angiogenesis. This study aims elaborate on association CCL2, IL18, IL23α, and TNF-α (tumor necrosis factor-alpha) expression with anti-proliferative effect ECCT rat tumor tissue. </ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> Low intensity (18 Vpp) intermediate frequency (150 kHz) alternating current-electric field (AC-EF) between two capacitive electrodes were exposed as external EF cage. Twenty-four rats divided into four groups six replicates. Breast tissues collected from 7, 12-dimethylbenz[a]anthracene (DMBA)-induced rats. Two none DMBA-induced without exposure (NINT) (NIT). The other (INT) (IT). Mammary glands each group preserved. Hematoxylin-eosin immunohistochemistry staining performed paraffin sections using anti-PCNA, anti-ErbB2, anti-Caspase3, anti-CD68. mRNA relative expressions analyzed qRT-PCR.</ns4:p><ns4:p> <ns4:bold>Results:</ns4:bold> may cause reduction PCNA protein well ErbB2 tissues, but it causes increase Caspase3 CD68 protein. In IT groups, CCL2 IL18 are significantly down-regulated, contrast up-regulated these cytokines INT group. IL23α TNF- α remained similar both groups.</ns4:p><ns4:p> <ns4:bold>Conclusion:</ns4:bold> have an inhibition cell proliferation affected by exposure</ns4:p>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (7)